Johnson & Johnson Sued for $70 Million Over Oral Cancer Test Detection
Source: Dr.Bicuspid.com July 8, 2011 -- Oral Cancer Prevention International (OCPI), makers of the Oral CDx brush test for oral cancer detection, is suing Johnson & Johnson (J&J) over a terminated distribution contract with OraPharma. OraPharma was previously a subsidiary of J&J until it was acquired last December by Water Street Healthcare Partners, a private equity firm in Chicago. J&J, which among other things sells Listerine mouthwash, was worried that a 2008 study linking alcohol-containing mouthwashes with oral cancer would negatively affect sales of Listerine and allegedly induced OraPharma to breach the sales agreement, according to OCPI. The lawsuit, filed July 6 in U.S. District Court, District of New Jersey, claims that J&J "maliciously and fraudulently" interfered with a contract between OCPI and OraPharma that gave OraPharma exclusive rights to sell the test to U.S. dentists. J&J's interference caused OraPharma "to suppress sales of and withhold from the public a proven lifesaving oral cancer prevention product in order to protect sales of its mouthwash, Listerine, which has been linked to oral cancer," according to the complaint. After OCPI signed the contract in February 2010, J&J did not want to "lend credence to the link between Listerine and oral cancer" by selling both its mouthwash and OralCDx, the complaint states. As of press time, J&J did not return calls for comment by DrBicuspid.com. Sales of Listerine bring in more than $1 billion per year, the suit claims. OralCDx is a "quick, painless, and inexpensive test that can prevent oral cancer by [...]